Open AccessAfatinib treatment of a squamous lung cancer after tumor progression of nivolumab
Author(s) -
Jin Yinghua,
Jiang Qiuying,
Xin Tao
Publication year - 2018
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.12522
Subject(s) - medicine , nivolumab , afatinib , lung cancer , refractory (planetary science) , immunotherapy , oncology , mediastinal lymph node , squamous cell carcinoma of the lung , squamous carcinoma , paralysis , cancer , metastasis , surgery , carcinoma , erlotinib , physics , epidermal growth factor receptor , astrobiology
Nivolumab prolonged disease control in a patient with advanced squamous lung cancer that was refractory to multiple treatments. The rapid eradication of cancer after the administration of nivolumab caused hemoptysis and repeated infection. Six months after immunotherapy, mediastinal lymph node metastasis developed and afatinib effectively relieved dysphonia associated with nerve paralysis.